JPWO2022000046A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022000046A5 JPWO2022000046A5 JP2022581380A JP2022581380A JPWO2022000046A5 JP WO2022000046 A5 JPWO2022000046 A5 JP WO2022000046A5 JP 2022581380 A JP2022581380 A JP 2022581380A JP 2022581380 A JP2022581380 A JP 2022581380A JP WO2022000046 A5 JPWO2022000046 A5 JP WO2022000046A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- formulation
- sequence shown
- formulation according
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000009472 formulation Methods 0.000 claims 34
- 239000000203 mixture Substances 0.000 claims 34
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 21
- 201000010099 disease Diseases 0.000 claims 17
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 235000018102 proteins Nutrition 0.000 claims 17
- 102000004169 proteins and genes Human genes 0.000 claims 17
- 108090000623 proteins and genes Proteins 0.000 claims 17
- 102000000429 Factor XII Human genes 0.000 claims 12
- 108010080865 Factor XII Proteins 0.000 claims 12
- 150000001413 amino acids Chemical class 0.000 claims 11
- 239000000872 buffer Substances 0.000 claims 10
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 9
- 229960002885 histidine Drugs 0.000 claims 9
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 9
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 9
- 229920000053 polysorbate 80 Polymers 0.000 claims 9
- 229940068968 polysorbate 80 Drugs 0.000 claims 9
- 229960002429 proline Drugs 0.000 claims 9
- KWTQSFXGGICVPE-WCCKRBBISA-N Arginine hydrochloride Chemical compound Cl.OC(=O)[C@@H](N)CCCN=C(N)N KWTQSFXGGICVPE-WCCKRBBISA-N 0.000 claims 7
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 7
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 7
- 239000000427 antigen Substances 0.000 claims 7
- 102000036639 antigens Human genes 0.000 claims 7
- 108091007433 antigens Proteins 0.000 claims 7
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 7
- 239000003381 stabilizer Substances 0.000 claims 7
- 208000007536 Thrombosis Diseases 0.000 claims 6
- 230000004913 activation Effects 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 4
- 206010051055 Deep vein thrombosis Diseases 0.000 claims 4
- 206010019860 Hereditary angioedema Diseases 0.000 claims 4
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 4
- 206010047249 Venous thrombosis Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 208000027866 inflammatory disease Diseases 0.000 claims 4
- 235000013930 proline Nutrition 0.000 claims 4
- 229940024606 amino acid Drugs 0.000 claims 3
- 235000001014 amino acid Nutrition 0.000 claims 3
- 230000003042 antagnostic effect Effects 0.000 claims 3
- 239000007853 buffer solution Substances 0.000 claims 3
- 239000002736 nonionic surfactant Substances 0.000 claims 3
- 210000000056 organ Anatomy 0.000 claims 3
- 150000007524 organic acids Chemical class 0.000 claims 3
- 238000002054 transplantation Methods 0.000 claims 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 2
- 201000006474 Brain Ischemia Diseases 0.000 claims 2
- 208000007257 Budd-Chiari syndrome Diseases 0.000 claims 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 2
- 206010008138 Cerebral venous thrombosis Diseases 0.000 claims 2
- 208000005189 Embolism Diseases 0.000 claims 2
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 2
- 206010048620 Intracardiac thrombus Diseases 0.000 claims 2
- 208000032382 Ischaemic stroke Diseases 0.000 claims 2
- 206010023237 Jugular vein thrombosis Diseases 0.000 claims 2
- 102000002397 Kinins Human genes 0.000 claims 2
- 108010093008 Kinins Proteins 0.000 claims 2
- 229930182821 L-proline Natural products 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 206010035664 Pneumonia Diseases 0.000 claims 2
- 201000009454 Portal vein thrombosis Diseases 0.000 claims 2
- 206010038548 Renal vein thrombosis Diseases 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 208000001435 Thromboembolism Diseases 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 229940090047 auto-injector Drugs 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 206010008118 cerebral infarction Diseases 0.000 claims 2
- 230000024203 complement activation Effects 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000020764 fibrinolysis Effects 0.000 claims 2
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 2
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 230000000926 neurological effect Effects 0.000 claims 2
- 229940071643 prefilled syringe Drugs 0.000 claims 2
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 2
- 230000010410 reperfusion Effects 0.000 claims 2
- 208000007056 sickle cell anemia Diseases 0.000 claims 2
- 208000020431 spinal cord injury Diseases 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 230000009529 traumatic brain injury Effects 0.000 claims 2
- 230000008728 vascular permeability Effects 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- 229920001213 Polysorbate 20 Polymers 0.000 claims 1
- 239000013011 aqueous formulation Substances 0.000 claims 1
- 235000009697 arginine Nutrition 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 229920001993 poloxamer 188 Polymers 0.000 claims 1
- 229940044519 poloxamer 188 Drugs 0.000 claims 1
- 229920005862 polyol Polymers 0.000 claims 1
- 150000003077 polyols Chemical class 0.000 claims 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 1
- 229940068977 polysorbate 20 Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20184004 | 2020-07-03 | ||
| EP20184004.8 | 2020-07-03 | ||
| PCT/AU2021/050714 WO2022000046A1 (en) | 2020-07-03 | 2021-07-05 | High concentration formulation of factor xii antigen binding proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023531315A JP2023531315A (ja) | 2023-07-21 |
| JPWO2022000046A5 true JPWO2022000046A5 (he) | 2024-07-12 |
Family
ID=71514949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022581380A Pending JP2023531315A (ja) | 2020-07-03 | 2021-07-05 | 第ｘｉｉ因子抗原結合タンパク質の高濃度製剤 |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP4175669A1 (he) |
| JP (1) | JP2023531315A (he) |
| KR (1) | KR20230035355A (he) |
| CN (1) | CN116322764A (he) |
| AU (1) | AU2021302684A1 (he) |
| BR (1) | BR112022026482A2 (he) |
| CA (1) | CA3183508A1 (he) |
| CL (1) | CL2023000004A1 (he) |
| IL (1) | IL298989A (he) |
| MX (1) | MX2022016365A (he) |
| WO (1) | WO2022000046A1 (he) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240216506A1 (en) * | 2021-05-12 | 2024-07-04 | Anaptysbio, Inc. | Antibody composition |
| WO2023115112A1 (en) * | 2021-12-20 | 2023-06-29 | CSL Innovation Pty Ltd | Protein formulations and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013014092A1 (en) * | 2011-07-22 | 2013-01-31 | Csl Behring Gmbh | Inhibitory anti -factor xii/xiia monoclonal antibodies and their uses |
| SG11201404481RA (en) * | 2012-03-08 | 2014-09-26 | Hoffmann La Roche | Abeta antibody formulation |
| US8613919B1 (en) * | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
| CA2993026A1 (en) * | 2015-07-21 | 2017-01-26 | Dyax Corp. | A monoclonal antibody inhibitor of factor xiia |
| AU2017238651B2 (en) * | 2016-03-25 | 2024-06-13 | Visterra, Inc. | Formulation of antibody molecules to dengue virus |
| AU2017247004B2 (en) * | 2016-04-06 | 2022-07-07 | Csl Limited | Method of treating atherosclerosis |
| AU2017380842A1 (en) * | 2016-12-23 | 2019-07-11 | Serum Institute Of India Private Limited | Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof |
| EP3886982A1 (en) * | 2018-11-28 | 2021-10-06 | Oregon Health & Science University | Therapeutic factor xii antibody |
-
2021
- 2021-07-05 WO PCT/AU2021/050714 patent/WO2022000046A1/en active Application Filing
- 2021-07-05 EP EP21834598.1A patent/EP4175669A1/en active Pending
- 2021-07-05 CA CA3183508A patent/CA3183508A1/en active Pending
- 2021-07-05 JP JP2022581380A patent/JP2023531315A/ja active Pending
- 2021-07-05 IL IL298989A patent/IL298989A/he unknown
- 2021-07-05 AU AU2021302684A patent/AU2021302684A1/en active Pending
- 2021-07-05 CN CN202180053399.8A patent/CN116322764A/zh active Pending
- 2021-07-05 MX MX2022016365A patent/MX2022016365A/es unknown
- 2021-07-05 BR BR112022026482A patent/BR112022026482A2/pt unknown
- 2021-07-05 KR KR1020237003982A patent/KR20230035355A/ko unknown
-
2023
- 2023-01-03 CL CL2023000004A patent/CL2023000004A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7080263B2 (ja) | 高濃度の抗ｖｅｇｆ抗体を含有する安定状態のタンパク質溶液製剤 | |
| US20200129600A1 (en) | Combination therapy using a factor xii inhibitor and a c-1 inhibitor | |
| KR20140066124A (ko) | 점도가 감소된 제제 | |
| CA2448345A1 (en) | Stable liquid formulations of antibodies | |
| IL298989A (he) | פרומולציה בריכוז גבוה של חלבונים קושרים לפקטור xii אנטיגן | |
| US20210046182A1 (en) | High concentration anti-c5 formulations | |
| KR20140018966A (ko) | 점도가 감소된 제제 | |
| JP7105260B2 (ja) | 免疫グロブリン単一可変ドメインでｔｔｐを処置する方法、およびその使用 | |
| JP2019509311A5 (he) | ||
| BR112013004850B1 (pt) | uso de um antagonista do tgf-b na preparação de um medicamento para tratamento de infarto do miocárdio | |
| JP2011518772A (ja) | フォンウィルブランド因子特異的結合因子及びこれらに関する使用方法 | |
| JP2019537617A5 (he) | ||
| JP2021534098A (ja) | 抗第ｘｉ因子抗体 | |
| JP2022105056A (ja) | 高濃度の抗ｖｅｇｆ抗体を含有するタンパク質溶液製剤 | |
| US20230174638A1 (en) | Formulations of anti-il-33 antibodies | |
| JPWO2022000046A5 (he) | ||
| WO2022106976A1 (en) | Stable pharmaceutical formulations of soluble fgfr3 decoys | |
| JP2022528230A (ja) | Ｉｌ－５に対する抗体を含有する医薬組成物及びその使用 | |
| JP2021501138A5 (he) | ||
| JP2021088548A (ja) | 安定な水性抗体製剤 | |
| CN118175993A (zh) | 一种抗sost抗体药物组合物及其用途 | |
| KR20240107348A (ko) | 안정적인 항체 치료제 | |
| BR112020015991A2 (pt) | Métodos de tratamento de episódio inicial de ttp com domínios variáveis únicos de imunoglobulina | |
| CN118176022A (zh) | 肺部病症中wnt信号传导的调节 | |
| EA046015B1 (ru) | Водная фармацевтическая композиция анти-il17a антитела и ее применение |